COMMUNIQUÉS West-GlobeNewswire

Healthcare Integrated Technologies welcomes former Google Executive & Head of Sales Enablement, Theo Davies as Chief Commercial Officer
09/12/2024
Nashville, TN, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Healthcare Integrated Technologies (OTC PINK: HITC), a global leader in AI-driven safety and monitoring solutions, proudly announces the appointment of Theo Davies as its [...]
UPDATE: MEDIROM Healthcare Technologies Has Received Orders for Over 25,000 MOTHER Bracelet Units
09/12/2024
TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that its subsidiary MEDIROM MOTHER Labs Inc. has received orders for over 25,000 MOTHER Bracelet units, [...]
T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens
09/12/2024
Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream LEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc [...]
Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m
08/12/2024
Étude du pétosemtamab en association avec le pembrolizumab en 1re ligne de traitement dans le CETC r/m exprimant PD-L1 en cours, avec une actualisation des données cliniques prévue pour 2025 L’évaluation du pétosemtamab [...]
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
08/12/2024
– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – – ENERGIZE-T is First Phase 3 Study to Demonstrate Efficacy of an Oral, [...]
TECVAYLI®▼ (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
08/12/2024
100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy 1 , 2 BEERSE, BELGIUM, Dec. 08, 2024 (GLOBE [...]
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
08/12/2024
In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across [...]
Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
08/12/2024
Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of Polivy in combination with R-CHP for people with first-line diffuse large B-cell [...]
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
08/12/2024
Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2% vs. 47.1%), meeting both ASC4FIRST 96-week key secondary endpoints [...]
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
08/12/2024
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with median duration of [...]
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
08/12/2024
The combination of acimtamig with AlloNK ® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, who have exhausted all standard of care treatments The [...]
DARZALEX® (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smouldering multiple myeloma
08/12/2024
First subcutaneous anti-CD38 therapy to demonstrate potential to prevent end-organ damage, and extend progression-free survival and overall survival based on findings from Phase 3 AQUILA study 1 BEERSE, BELGIUM, Dec. 08 [...]
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
08/12/2024
Media Release COPENHAGEN, Denmark; December 8, 2024 Preliminary analyses from the EPCORE ® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily [...]
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
08/12/2024
Media Release COPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with [...]
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
08/12/2024
Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate dehydrogenase (LDH) levels, [...]
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
08/12/2024
New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10 -6 provides more accurate assessment of treatment responses [...]
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
07/12/2024
Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes studied. 96% of patients [...]
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
07/12/2024
NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
07/12/2024
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP Pivotal phase 3 data show rapid and durable platelet response, reduced bleeding and need for [...]

Pages